Advertisement

Topics

AbbVie, Voyager set sights on 'one-time' Alzheimer's treatment

03:58 EST 20 Feb 2018 | BioPharmaDive

Gene therapies targeting tau proteins are at the center of AbbVie's latest deal focused on the neurodegenerative disorder.

Original Article: AbbVie, Voyager set sights on 'one-time' Alzheimer's treatment

NEXT ARTICLE

More From BioPortfolio on "AbbVie, Voyager set sights on 'one-time' Alzheimer's treatment"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...